Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Shineway Pharmaceutical Group Limited ( (HK:2877) ) has shared an announcement.
China Shineway Pharmaceutical Group Limited has scheduled a board meeting in Hong Kong on 27 March 2026 to review and approve the annual results for the year ended 31 December 2025. The board will also consider declaring a dividend at the same meeting, a move that could directly affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also reconfirms the current composition of the company’s board, including its executive, non-executive, and independent non-executive directors. This disclosure underscores ongoing corporate governance transparency for investors as the company approaches the release of its full-year financial results.
The most recent analyst rating on (HK:2877) stock is a Buy with a HK$11.00 price target. To see the full list of analyst forecasts on China Shineway Pharmaceutical Group Limited stock, see the HK:2877 Stock Forecast page.
More about China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands, operating in the healthcare and drug manufacturing industry. The group focuses on developing, producing, and selling pharmaceutical products through its subsidiaries, targeting medical and consumer markets in mainland China and beyond.
Average Trading Volume: 1,053,057
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$6.96B
For an in-depth examination of 2877 stock, go to TipRanks’ Overview page.